AGENDA: Adavanced Glycated Endproducts and Development of CAD

Sponsor

Shanghai Jiao Tong University School of Medicine (Other)

Overall Status

Unknown status

CT.gov ID

NCT02089360

Collaborator

(none)

10,000

Enrollment

Location

Study Details

Study Description

Brief Summary

Blood sample is prospectively taken from consecutive patients underwent coronary angiogram in our center, after getting informed consent from the patients. Serum level of advanced glycation end products (AGEs) was measured and the clinical features of patients (including angiographic results) were entered into our database. Clinical follow-up was performed for all patients, and the relationship between AGEs and paitents' outcome were analyzed. Further intervention will be adjusted according to the results,including clinical and basic research in lab.

Condition or Disease	Intervention/Treatment	Phase
Atherosclerosis Inflammation

Detailed Description

Serum levels of HMGB1, HMGB2, ADAM10, etc. will be measured in lab and animal studies will be designed to intervene the adverse interaction between abnormal serum concentration of AGEs, etc. and worse clinical results.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

10000 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Study of Serum Level of Advanced Glycated Endproducts and Development of Coronary Atherosclerosis in Patients Undergoing Coronary Angiogram

Study Start Date :

Jan 1, 2014

Anticipated Primary Completion Date :

Jan 1, 2016

Outcome Measures

Primary Outcome Measures

MACE [5-year]
including death, occurrence of myocardial infarction, and coronary revascularization

Secondary Outcome Measures

progression in coronary atherosclerosis [5-year]
repeated coronary angiogram in patients with symptom aggravation or occurrence of myocardial infarction, to evaluate the progression of coronary lesions, comparing to the baseline results.

Other Outcome Measures

Serum level of AGEs [baseline]
serum levels of AGEs will be measured and the relationship between clinical outcomes will be analyzed.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 90 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

patients underwent coronary angiogram for suspected coronary artery disease and potential percutaneous coronary intervention

Exclusion Criteria:

patients underwent coronary angiogram for other reasons, including pre-surgery examination
patients with severe co-morbidity, and life expectancy less than one-year